POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

被引：0
|
作者：
An, Yoon-Kyo
Lindsay, Niamh
Allan, Natalie
Khoo, Emi
Fernandes, Richard
Amiss, Anna
Hai Pham
Wong, Kam Fai
Ooi, Soong-Yuan
Thin, Lena
Lightowler, Daniel
Connor, Susan J.
Williams, Astrid-Jane
De Cruz, Peter
Suen, Christopher Li Wai
Kariyawasam, Viraj C.
Mitrev, Nikola
Ghaly, Simon
Andrews, Jane M.
Christensen, Britt
Sparrow, Miles
White, Lauren S.
Bryant, Robert V.
Ding, Nik S.
Leong, Rupert
Van Langenberg, Daniel R.
Seltenreich, Hansjoerg
Subramaniam, Kavitha
Radford-Smith, Graham L.
Begun, Jakob
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1749
引用
收藏
页码：S1108 / S1108
页数：1
相关论文
共 50 条
  • [41] Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
    Proietti, Elisa
    Pauwels, Renske W. M.
    van der Woude, Christien J.
    Doukas, Michael
    Oudijk, Lindsey
    Peppelenbosch, Maikel P.
    Grohmann, Ursula
    Crombag, Marie-Rose B. S.
    de Vries, Annemarie C.
    Fuhler, Gwenny M.
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (07) : 1038 - 1046
  • [42] USTEKINUMAB FOR THE TREATMENT OF SYMPTOMATIC SMALL BOWEL STRICTURING CROHN'S DISEASE - RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY
    El Ouali, Sara
    Baker, Mark E.
    Lu, Cathy
    Medellin, Alexandra
    Bruining, David H.
    Fletcher, Joel G.
    Ottichilo, Ronald K.
    Schoenoff, Shayla
    Bena, James
    Qazi, Taha
    Sleiman, Joseph
    Holubar, Stefan D.
    Gandhi, Namita S.
    Cohen, Benjamin L.
    Goren, Idan
    Balci, Numan
    Rieder, Florian
    GASTROENTEROLOGY, 2023, 164 (06) : S1010 - S1010
  • [43] VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SYMPTOMATIC SMALL BOWEL STRICTURING CROHN'S DISEASE - RESULTS FROM AN OBSERVATIONAL COHORT STUDY
    El Ouali, Sara
    Ottichilo, Ronald K.
    Atkinson, Norma
    Lu, Cathy
    Bruining, David H.
    Qazi, Taha
    Achkar, Jean-Paul
    Sleiman, Joseph
    Holubar, Stefan D.
    Baker, Mark E.
    Gandhi, Namita S.
    Fletcher, Joel G.
    Click, Benjamin H.
    Cohen, Benjamin L.
    Rieder, Florian
    GASTROENTEROLOGY, 2021, 160 (06) : S713 - S713
  • [44] Ustekinumab tissue and serum levels in patients with Crohn's disease are closely correlated though not consistently associated with objective response after induction
    Proietti, E.
    Bayoumy, A.
    Pauwels, R.
    van der Woude, J.
    Doukas, M.
    Oudijk, L.
    Peppelenbosch, M.
    Grohmann, U.
    Crombag, R.
    de Vries, A.
    Fuhler, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I500 - I501
  • [45] Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China
    Li, Ping
    Wang, Lin
    Tang, Zifei
    Wang, Yuhuan
    Liu, Zhanju
    Ge, Wensong
    Huang, Ying
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [46] EFFECT OF SKIN SYMPTOMS ON DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING THE IL-12/23 INHIBITOR USTEKINUMAB OR TNF INHIBITORS IN THE REAL-WORLD PSABIO STUDY
    Smolen, J. S.
    Korotaeva, T.
    Nurmohamed, M.
    Siebert, S.
    Bergmans, P.
    De Vlam, K.
    Gremese, E.
    Joven-Ibanez, B.
    Noel, W.
    Sfikakis, P.
    Theander, E.
    Gossec, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1295 - 1296
  • [47] Ustekinumab in Crohn's disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safety
    Barkai, L. J.
    Gonczi, L.
    Farkas, K.
    Farkas, B.
    Molnar, T.
    Szamosi, T.
    Schafer, E.
    Golovics, P.
    Juhasz, M.
    Patai, A.
    Vincze, A.
    Sarlos, P.
    Farkas, A.
    Dubravcsik, Z.
    Toth, T. G.
    Miheller, P.
    Lakatos, P. L.
    Ilias, A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1249 - I1249
  • [48] Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet’s patients
    Cemile Sonmez
    Aysegul Atak Yucel
    Turan Hilmi Yesil
    Hamit Kucuk
    Berna Sezgin
    Ridvan Mercan
    Ahmet Eftal Yucel
    Gulderen Yanikkaya Demirel
    Clinical Rheumatology, 2018, 37 : 2797 - 2804
  • [49] Effectiveness of dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
    Kopylov, U.
    Hanzel, J.
    Liefferinckx, C.
    De Marco, D.
    Imperatore, N.
    Plevris, N.
    Baston-Rey, I.
    Harris, R.
    Truyens, M.
    Domislovic, V.
    Vavricka, S.
    Biemans, V.
    Myers, S.
    Shaji, S.
    Ben-Horin, S.
    Gonzalez Lama, Y.
    Gilletta, C.
    Shitrit, A. Bar-Gil
    Zelinkova, Z.
    Weishof, R.
    Storan, D.
    Zittan, E.
    Franchimont, D.
    Cremer, A.
    Afif, W.
    Castiglione, F.
    Lees, C.
    Barrero de Acosta, M.
    Lobaton, T.
    Doherty, G.
    Krznaric, Z.
    Pierik, M.
    Hoentjen, F.
    Drobne, D.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S111 - S111
  • [50] Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients
    Sonmez, Cemile
    Yucel, Aysegul Atak
    Yesil, Turan Hilmi
    Kucuk, Hamit
    Sezgin, Berna
    Mercan, Ridvan
    Yucel, Ahmet Eftal
    Demirel, Gulderen Yanikkaya
    CLINICAL RHEUMATOLOGY, 2018, 37 (10) : 2797 - 2804
12345